Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Inclusion Criteria: * Cannot be included in an ongoing clinical study and cannot be satisfactorily treated with a product that has regulatory approval * Is ≥18 years of age at the time of signing the informed consent form * Patient has a diagnosis of CIDP according to the 2021 EAN/PNS CIDP guidelines * Patient has progressive or relapsing active disease after prior treatment with corticosteroids or immunoglobulins Exclusion Criteria: * Known autoimmune disease or any medical condition that, in the opinion of the treating physician, would interfere with an accurate assessment of clinical symptoms of CIDP or that puts the patient at undue risk * Is currently being treated or plans to start treatment with monoclonal antibodies or treatments that contain the human Fc domain of the IgG subclass * Pregnant or lactating state or intention to become pregnant during the program